Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer (Q85111035)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20880998 AND SRC:MED&resulttype=core&format=json

14 February 2020

title

Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20880998 AND SRC:MED&resulttype=core&format=json

14 February 2020

1 reference

1 reference

J. Flanagan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:20880998

23 July 2024

P. Kathryn Gray

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:20880998

23 July 2024

N. Hahn

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:20880998

23 July 2024

J. Hayes

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:20880998

23 July 2024

L. J. Myers

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:20880998

23 July 2024

C. Carney-Doebbeling

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:20880998

23 July 2024

C. J. Sweeney

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:20880998

23 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20880998

23 July 2024

publication date

29 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20880998 AND SRC:MED&resulttype=core&format=json

full work available at URL

14 February 2020

http://www.annalsofoncology.org/article/S0923753419385527/pdf

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:20880998

http://annonc.oxfordjournals.org/cgi/content/abstract/22/4/801

23 July 2024

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:20880998

https://api.elsevier.com/content/article/PII:S0923753419385527?httpAccept=text/xml

23 July 2024

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

https://api.elsevier.com/content/article/PII:S0923753419385527?httpAccept=text/plain

23 July 2024

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

http://academic.oup.com/annonc/article-pdf/22/4/801/568490/mdq443.pdf

23 July 2024

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

23 July 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20880998 AND SRC:MED&resulttype=core&format=json

14 February 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20880998 AND SRC:MED&resulttype=core&format=json

14 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20880998 AND SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

801-807

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20880998 AND SRC:MED&resulttype=core&format=json

14 February 2020

cites work

Cancer statistics, 2008

1

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

23 July 2024

2

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack: a prospective cohort study in patients with atherosclerotic cardiovascular disease

23 July 2024

3

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults

23 July 2024

4

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

23 July 2024

5

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

Relationship between obesity and prostate cancer

23 July 2024

6

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

The metabolic syndrome: A high-risk state for cancer?

23 July 2024

7

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer

23 July 2024

8

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

Hypertension, heart rate, use of antihypertensives, and incident prostate cancer

23 July 2024

9

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

Height, body weight, and risk of prostate cancer

23 July 2024

10

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

Self-reported history of hypercholesterolaemia and gallstones and the risk of prostate cancer

23 July 2024

11

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years

23 July 2024

13

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

The metabolic syndrome is associated with reduced risk of prostate cancer

23 July 2024

14

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

Obesity, Diabetes, and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial

23 July 2024

15

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group

23 July 2024

16

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.

23 July 2024

17

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome

23 July 2024

18

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

Prostate cancer: another aspect of the insulin-resistance syndrome?

23 July 2024

19

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study

23 July 2024

20

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice

23 July 2024

21

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

23 July 2024

23

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

Low testosterone levels and unimpaired melatonin secretion in young males with metabolic syndrome

23 July 2024

24

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

Obesity, Adipokines, and Prostate Cancer in a Prospective Population-Based Study

23 July 2024

25

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

Role of leptin in the cardiovascular and endocrine complications of metabolic syndrome.

23 July 2024

26

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

Prostate cancer cell-adipocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase

23 July 2024

27

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

Prostate cancer and adiponectin.

23 July 2024

28

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

Intermittent calorie restriction delays prostate tumor detection and increases survival time in TRAMP mice

23 July 2024

29

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease

23 July 2024

30

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis

23 July 2024

31

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

Insulin sensitivity: modulation by nutrients and inflammation

23 July 2024

32

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome

23 July 2024

33

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

23 July 2024

34

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Farooki and Schneider

23 July 2024

35

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer

23 July 2024

36

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study

23 July 2024

37

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

23 July 2024

38

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

Metformin decreases angiogenesis via NF-kappaB and Erk1/2/Erk5 pathways by increasing the antiangiogenic thrombospondin-1.

23 July 2024

39

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ443

23 July 2024

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20880998 AND SRC:MED&resulttype=core&format=json

14 February 2020

1 reference